Glooko Announces Partnership with Insulin Dosing Algorithm Company Hedia USA - English Danmark - English Danmark - Dansk Deutschland - Deutsch España - español Italia - Italiano France - Français
The Californer/10236316

Trending...
PALO ALTO, Calif., April 11, 2023 ~ Glooko Inc. and Hedia have announced a new global partnership, integrating Hedia's technology into Glooko's diabetes management platforms for healthcare providers and people with diabetes. The collaboration will provide an interoperable solution that brings together connected care, remote patient monitoring and digital therapeutic technologies to enhance access for people with Type 1 and Type 2 diabetes requiring bolus insulin dosing advice.

The Glooko platforms allow patients to share their diabetes data with their healthcare providers (HCPs), including blood glucose readings, insulin doses, food and carbs, exercise activity, blood pressure and weight. With the integration of Hedia Diabetes Assistant, people with diabetes will be able to receive bolus insulin dosing advice which will provide personalized care and reduce the burden of manually calculating required insulin doses. In addition, when used in conjunction with connected insulin pens*, the integrated solution facilitates a high level of visibility for HCPs who are managing patients on multiple daily injection (MDI) therapy. This integration enhances the capabilities of Glooko's remote patient monitoring (RPM) and supports virtual consultations for MDI patients.

More on The Californer
Glooko CEO Russ Johannesson expressed his pleasure at the partnership saying "We are very pleased to partner with Hedia to offer this algorithm-driven innovation for personalized healthcare for diabetes patients and their healthcare teams. The robust clinical data supporting Hedia's efficacy demonstrates this could be a viable alternative for patients who are not able to access insulin pumps. This partnership shows how interoperability gives people with diabetes the optimal tools available to ease the management of their condition and enhance health outcomes such as the stability of blood glucose levels."

Hedia CEO Peter Lucas also commented on the partnership saying "We are thrilled to call Glooko, a company with such an extensive clinical network, our partner in digital health. In addition to our strong clinical evidence, one of the key issues we consider when building our technology is regulatory compliance and cybersecurity. Glooko has demonstrated their strength in these areas with multiple third-party certifications and that's a key driver behind our partnership. Hedia's Class IIb medical device designation ensures that the best solutions are being provided to patients and their care teams."

More on The Californer
The initial European launch of the integration is expected in late 2023 or early 2024*.

This new collaboration between Glooko Inc. and Hedia promises improved access for people with Type 1 or Type 2 diabetes requiring bolus insulin dosing advice through an interoperable solution that brings together connected care, remote patient monitoring and digital therapeutic technologies. With this integration comes enhanced capabilities for both healthcare providers managing MDI therapy as well as virtual consultations for MDI patients while providing personalized care through bolus insulin dosing advice which reduces manual calculations required by those living with diabetes.*The connected pen feature is available only in the EU
Filed Under: Business

Show All News | Report Violation

0 Comments

Latest on The Californer